Brexpiprazole

Category: pharmacological

Aliases: Rexulti

Pharmacological Mechanism

Atypical antipsychotic — D2 + 5-HT1A partial agonist + 5-HT2A antagonist. Lower akathisia + activation than aripiprazole. Approved for schizophrenia + adjunct in MDD + Alzheimer-related agitation (2023).

Half-Life (t½)

PO: 91h

Dosing Guidelines

• PO: Typical 2mg (Range: 0.25 - 4 mg)

Target Organ Systems

• nervous